Omalizumab, a monoclonal antibody commonly used to treat severe allergic asthma, may help reduce reliance on daily inhaled corticosteroids when combined with allergen immunotherapy for house dust mites in patients with mild-to-moderate allergic asthma, according to recent findings highlighted in medical news.
This potential benefit stems from the drug’s mechanism of targeting immunoglobulin E (IgE), a key antibody involved in allergic reactions. By binding to free IgE, omalizumab prevents it from triggering the cascade of immune responses that lead to airway inflammation and asthma symptoms. When paired with allergen-specific immunotherapy—which gradually desensitizes the immune system to house dust mite allergens—the combination may offer a synergistic effect, improving long-term control of allergic asthma.
House dust mites are among the most common indoor allergens worldwide, particularly in humid climates, and are a major trigger for allergic asthma. Symptoms such as wheezing, shortness of breath, chest tightness, and nighttime coughing often worsen with exposure to these microscopic organisms found in bedding, upholstered furniture, and carpets. For many patients, managing this condition requires daily use of inhaled corticosteroids to control inflammation, though long-term use can raise concerns about side effects, prompting interest in steroid-sparing strategies.
Recent research suggests that adding omalizumab to standard allergen immunotherapy may allow some patients to lower or maintain reduced doses of inhaled corticosteroids without losing asthma control. A prospective cohort study conducted in China and published in the Journal of Asthma and Allergy in September 2025 followed patients with moderate-to-severe allergic asthma who received either allergen immunotherapy alone or in combination with omalizumab. The study found that those receiving the combination therapy showed improved clinical outcomes, including reduced medication burden and enhanced quality of life, over the treatment period.
Another line of evidence comes from a 2026 study published in Allergy and Asthma Proceedings, which compared long-term outcomes of omalizumab monotherapy, subcutaneous allergen immunotherapy (SCIT) for house dust mites, and their combination in mild-to-moderate allergic asthma. Over a three-year follow-up, researchers observed that the combination group demonstrated sustained improvements in lung function, fewer exacerbations, and greater reductions in inhaled corticosteroid use compared to either treatment alone.
These findings are particularly relevant given the global burden of allergic asthma, which affects an estimated 300 million people worldwide. Although inhaled corticosteroids remain a cornerstone of asthma management due to their effectiveness in reducing airway inflammation, identifying safe and effective ways to minimize their long-term use is an important goal in personalized asthma care. Strategies that combine biologics like omalizumab with immunomodulatory approaches such as allergen immunotherapy represent a growing area of interest in precision medicine for allergic diseases.
Omalizumab, first approved by the U.S. Food and Drug Administration (FDA) in 2003 for moderate-to-severe persistent allergic asthma, is administered via subcutaneous injection every two or four weeks, depending on the patient’s IgE level and body weight. We see typically reserved for patients who remain symptomatic despite high-dose inhaled corticosteroids and long-acting beta-agonists. Its use in milder forms of asthma, particularly when combined with immunotherapy, is still under investigation but shows promise in select populations.
Allergen immunotherapy, whether delivered subcutaneously (as allergy shots) or sublingually (as tablets or drops), works by gradually increasing exposure to specific allergens to retrain the immune system’s response. For house dust mite immunotherapy, treatment usually spans three to five years to achieve lasting tolerance. When initiated alongside omalizumab, the biologic may help mitigate early-phase allergic reactions during the buildup phase of immunotherapy, potentially improving safety and adherence.
Experts caution that while the combination approach appears promising, it is not suitable for all patients. Factors such as specific IgE levels, comorbid conditions, access to specialist care, and treatment burden must be considered. Omalizumab carries a boxed warning for anaphylaxis, requiring administration in a healthcare setting equipped to manage severe allergic reactions. Patients considering this treatment path should consult with an allergist or pulmonologist experienced in biologic therapies and immunotherapy.
Ongoing research continues to refine patient selection criteria and optimize treatment protocols. Real-world studies and longitudinal registries are helping clarify which subgroups benefit most from combining omalizumab with allergen immunotherapy—whether based on biomarkers, symptom severity, or sensitization patterns. As more data emerge, clinical guidelines may evolve to reflect these combination strategies in the management of allergic asthma.
For patients and caregivers navigating treatment options, staying informed through trusted medical sources and discussing individualized plans with healthcare providers remains essential. While no single approach works for everyone, the growing evidence supporting integrated therapies offers hope for better control, reduced medication dependence, and improved daily living for those affected by allergic asthma.
As research progresses, the next key checkpoint will be the presentation of long-term safety and efficacy data from ongoing clinical trials at major respiratory medicine conferences, including the European Respiratory Society (ERS) International Congress and the American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting. These forums often feature updates on biomarker-driven treatment approaches and real-world outcomes in biologic therapy.
Readers are encouraged to share their experiences or questions in the comments below and to share this article with others who may find it informative. Stay tuned to World Today Journal for continued coverage of advances in respiratory health and allergy treatment.